Biohaven ends psychiatric push for BHV-7000 after Phase 2 trial in depression fails to show efficacy

By on    Pharma & Biotech  

Biohaven ends psychiatric push for BHV-7000 after Phase 2 trial in depression fails to show efficacy

Biohaven Ltd. has reported that BHV-7000, its experimental Kv7 ion channel modulator, failed to meet the primary endpoint in a Phase 2 proof-of-concept trial evaluating the drug in patients with major depressive disorder. The trial assessed changes in depressive symptoms using the Montgomery-Åsberg Depression Rating Scale over six weeks compared to placebo. Although some numerical […]

Can Biohaven’s BHV-1510 avoid the safety pitfalls of existing Trop2 ADCs in solid tumors?

By on    Pharma & Biotech  

Can Biohaven’s BHV-1510 avoid the safety pitfalls of existing Trop2 ADCs in solid tumors?

Biohaven Ltd. presented updated Phase 1 clinical data on BHV-1510, its next-generation Trop2-targeting antibody-drug conjugate, at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London. The results, derived from a heavily pretreated population with advanced or metastatic solid tumors, showed encouraging response rates across non-small cell lung cancer, endometrial cancer, and urothelial […]